ArrowMark Colorado Holdings’s Immunovant IMVT Stock Holding History

ArrowMark Colorado Holdings’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.74M	Hold	70,000	–	–	0.05%	227
2025 Q4	$1.78M	Hold	70,000	–	–	0.04%	249
2025 Q3	$1.13M	Hold	70,000	–	–	0.02%	250
2025 Q2	$1.12M	Hold	70,000	–	–	0.02%	252
2025 Q1	$1.2M	Hold	70,000	–	–	0.02%	243
2024 Q4	$1.73M	Hold	70,000	–	–	0.02%	240
2024 Q3	$2M	Hold	70,000	–	–	0.03%	230
2024 Q2	$1.85M	Hold	70,000	–	–	0.02%	245
2024 Q1	$2.26M	Sell	70,000 -3,550	-5%	-$130K	0.03%	240
2023 Q4	$3.1M	Hold	73,550	–	–	0.03%	222
2023 Q3	$2.82M	Buy	+73,550	New	+$1.66M	0.03%	217

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ArrowMark Colorado Holdings's IMVT Position: Q1 2026 in Review

ArrowMark Colorado Holdings held its Immunovant (IMVT) position steady in Q1 2026 at 70,000 shares worth $1.74M. The position accounts for 0.05% of the portfolio, ranked #227.

ArrowMark Colorado Holdings first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.1M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

ArrowMark Colorado Holdings held 70,000 shares of Immunovant worth $1.74M as of Q1 2026.
ArrowMark Colorado Holdings left its Immunovant share count unchanged in Q1 2026.
Immunovant made up 0.05% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #227 holding.
ArrowMark Colorado Holdings first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
ArrowMark Colorado Holdings's Immunovant position peaked at $3.1M in Q4 2023.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.